These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 15529157)

  • 21. Can China bring its own pipeline to the market?
    Louët S
    Nat Biotechnol; 2004 Dec; 22(12):1497-9. PubMed ID: 15583646
    [No Abstract]   [Full Text] [Related]  

  • 22. Rediscovering plant-based drugs.
    Littleton J; Falcone D; Davies HM
    Nat Biotechnol; 2003 Aug; 21(8):843-4. PubMed ID: 12894188
    [No Abstract]   [Full Text] [Related]  

  • 23. Trading on traditional medicines.
    Basu P
    Nat Biotechnol; 2004 Mar; 22(3):263-5. PubMed ID: 14990941
    [No Abstract]   [Full Text] [Related]  

  • 24. Commercializing nanotechnology.
    Mazzola L
    Nat Biotechnol; 2003 Oct; 21(10):1137-43. PubMed ID: 14520392
    [No Abstract]   [Full Text] [Related]  

  • 25. Deconstructing Myogen's market cap.
    Ransom J
    Nat Biotechnol; 2006 Mar; 24(3):227-8. PubMed ID: 16525363
    [No Abstract]   [Full Text] [Related]  

  • 26. Cambridge: Europe's leading location for biotechnology.
    Walker J
    Drug Discov Today; 2005 Jul; 10(14):956-9. PubMed ID: 16023052
    [No Abstract]   [Full Text] [Related]  

  • 27. Seizures of Canadian drugs rise as Congress, Customs spar.
    Carreyrou J
    Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16909501
    [No Abstract]   [Full Text] [Related]  

  • 28. The 802 million dollars fallacy.
    Hodgson J
    Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
    [No Abstract]   [Full Text] [Related]  

  • 29. FDA chief attacks Canada's drug price controls.
    Webster P
    Lancet; 2003 Nov; 362(9398):1816. PubMed ID: 14661624
    [No Abstract]   [Full Text] [Related]  

  • 30. Manufacturing in China.
    Med Device Technol; 2005 Nov; 16(9):48-9. PubMed ID: 16438451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maturing biotechs turn to pharma's markets.
    Ratner M
    Nat Biotechnol; 2005 Mar; 23(3):269. PubMed ID: 15765067
    [No Abstract]   [Full Text] [Related]  

  • 32. Should platform companies move toward products?
    Ratner M
    Nat Biotechnol; 1999 Jan; 17(1):16-7. PubMed ID: 9920255
    [No Abstract]   [Full Text] [Related]  

  • 33. Private company profiles.
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE23-8. PubMed ID: 12874973
    [No Abstract]   [Full Text] [Related]  

  • 34. Advice for partnering with pharma.
    Howard K
    Nat Biotechnol; 2004 Nov; 22(11):1477-9. PubMed ID: 15586421
    [No Abstract]   [Full Text] [Related]  

  • 35. Uncorking the biomanufacturing bottleneck.
    Dove A
    Nat Biotechnol; 2002 Aug; 20(8):777-9. PubMed ID: 12148000
    [No Abstract]   [Full Text] [Related]  

  • 36. Strategies for developing and commercializing nanobio drugs, diagnostics and devices.
    Bunger M
    Nanomedicine (Lond); 2007 Apr; 2(2):137-41. PubMed ID: 17716115
    [No Abstract]   [Full Text] [Related]  

  • 37. A quiet revolution in lead optimisation services?
    Cavalla D
    Drug Discov Today; 2004 Aug; 9(15):635-6. PubMed ID: 15279844
    [No Abstract]   [Full Text] [Related]  

  • 38. Brokering knowledge in biosciences with InnoCentive. Interview by Semahat S. Demir.
    Hussein A
    IEEE Eng Med Biol Mag; 2003; 22(4):26-7. PubMed ID: 14515687
    [No Abstract]   [Full Text] [Related]  

  • 39. Betting on biogenerics.
    Dove A
    Nat Biotechnol; 2001 Feb; 19(2):117-20. PubMed ID: 11175723
    [No Abstract]   [Full Text] [Related]  

  • 40. China's biotech is starting to bloom.
    Stipp D
    Fortune; 2002 Sep; 146(4):126-30, 132, 134. PubMed ID: 12195673
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.